The Global healthcare company Novo Nordisk is introducing a new generation of obesity treatments in the Philippines, reinforcing its long-standing commitment to improving care for people living with obesity and diabetes.
The treatments, called GLP-1 receptor agonists, mimic a natural hormone that helps control hunger and blood sugar. They can help patients feel full longer, reduce cravings, and improve blood sugar control for people with diabetes. Studies show these medicines can reduce body weight by 15 percent to 25 percent within a year, offering results similar to surgical interventions but without invasive procedures.
“This is a new era in obesity care in the country,” said Wei Sun, general manager of Novo Nordisk Philippines. “For years, people with obesity have faced limited options and stigma. Now, treatments that work with the body’s natural systems could transform outcomes across the Philippines.”
Novo Nordisk also stresses patient safety, urging people to consult healthcare professionals and avoid unregulated or compounded medications, which can be unsafe and ineffective.
Beyond treatments, the company is working to raise awareness of obesity as a chronic disease, provide medical education for healthcare professionals, and expand access to safe, evidence-based care.
